Disparities in the practice of precision medicine? Using multi-gene testing in early-stage, HR+/HER2-breast cancer

被引：0
|
作者：
Bilani, Nadeem
Yaghi, Marita
Saravia, Diana
Jabbal, Iktej
Zerdan, Maroun Bou
Elson, Leah
Hong, Liang
Nahleh, Zeina
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P1-08-33
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-08-33
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk
    Sarkar, Swarnavo
    Schechter, Clyde
    Kurian, Allison W.
    Caswell-Jin, Jennifer L.
    Jayasekera, Jinani
    Mandelblatt, Jeanne S.
    NPJ BREAST CANCER, 2025, 11 (01)
  • [42] Conventional Tools for Predicting Satisfactory Response to Neoadjuvant Chemotherapy in HR+/HER2-Breast Cancer Patients
    Oprea, Adela Luciana
    Gulluoglu, Bahadir
    Aytin, Yusuf Emre
    Eren, Ozgur Can
    Aral, Canan
    Szekely, Tiberiu-Bogdan
    Tastekin, Ebru
    Kaya, Handan
    Bademler, Sueleyman
    Karanlik, Hasan
    Sezer, Atakan
    Ugurlu, Mustafa Umit
    Turdean, Sabin Gligore
    Georgescu, Rares
    Marginean, Claudiu
    BREAST CARE, 2023, 18 (05) : 344 - 353
  • [43] Quality care of patients with HR+/HER2-breast cancer: Insights from an implementation science program
    McKinnon, Kelly E.
    O'Shaughnessy, Joyce
    Gurska, Lindsay
    Carter, Jeffrey D.
    Heggen, Cherilyn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] TREATMENT PATTERNS AND PROGNOSTIC FACTORS OF LOCALLY ADVANCED OR METASTATIC HR+ / HER2-BREAST CANCER IN ARGENTINA
    Novick, D.
    Moneta, M., V
    Fischman, M.
    Zarino, N.
    Gallino, J.
    Carter, Cuyun G.
    Haro, J. M.
    VALUE IN HEALTH, 2020, 23 : S62 - S63
  • [45] Vitamin A Metabolism Induces Ferroptosis to Enhance Immune Therapy Efficacy in HR+/HER2-Breast Cancer
    Zhou, Yi-Fan
    Zhang, Hu-Yun-Long
    Jin, Xi
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    CANCER RESEARCH, 2024, 84 (09)
  • [46] Patient-reported and cancer-specific health-related quality of life among patients with early stage HR+/HER2-breast cancer (BC)
    Criscitiello, C.
    Spurden, D.
    Rider, A.
    Williams, R.
    Corsaro, M.
    Pike, J.
    Law, E. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S44 - S45
  • [47] Racial/ethnic disparities in the survival of HR+/HER2-early breast cancer using the CPS plus EG scoring system
    Hanson, Kent A.
    Hoskins, Kent F.
    Ko, Naomi Y.
    Calip, Gregory S.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (01)
  • [48] Age and competing concerns in treatment selection for women with non-metastatic HR+ and HER2-breast cancer: Current clinical practice
    Lorentsen, Michael K.
    Vohra, Sanah
    Muss, Hyman B.
    Damone, Emily
    Deal, Allison M.
    Brenizer, Addison Tucker
    Nyrop, Kirsten A.
    JOURNAL OF GERIATRIC ONCOLOGY, 2022, 13 (06) : 839 - 843
  • [49] Clinical outcome for HR+/HER2-stage IV breast cancer patients
    Goto, Risa
    Aruga, Tomoyuki
    Honda, Yahoi
    Idera, Nami
    Horiguchi, Kazumi
    Miyamoto, Hiromi
    Yamashita, Toshinari
    Horiguchi, Shinnichiro
    Kuroi, Katsumasa
    ANNALS OF ONCOLOGY, 2015, 26 : 142 - 142
  • [50] PREDICTING OPTIMAL TREATMENT REGIMENS FOR HR+/HER2-BREAST CANCER BASED ON ELECTRONIC HEALTH RECORDS USING RANDOM FOREST
    Cui, Z.
    Kadziola, Z.
    Faries, D. E.
    Lipkovich, I
    Ratitch, B.
    Li, X.
    Sheffield, K.
    Carter, Cuyun G.
    VALUE IN HEALTH, 2020, 23 : S8 - S9
12345